Patent application number | Description | Published |
20130337533 | Compositions for Diagnosis and Therapy of Diseases Associated with Aberrant Expression of Futrins (R-Spondins) and/or Wnt - The present invention relates to a composition useful for the diagnosis of diseases associated with aberrant expression of the genes encoding the secreted proteins Futrin 1, 2, 3 and/or 4(=R-Spondin 2, 3, 1 and 4, respectively), e.g. in connection with tumors or diseases of the muscle, kidneys or bones. The present invention also relates to a pharmaceutical composition containing a compound which is capable of modifying (a) the expression of the gene encoding Futrin 1, 2, 3 and/or 4 or (b) the activity of the Futrin 1, 2, 3 and/or 4 protein. | 12-19-2013 |
20140134703 | Compositions for Diagnosis and Therapy of Diseases Associated with Aberrant Expression of Futrins (R-Spondins) and/or Wnt - The present invention relates to a composition useful for the diagnosis of diseases associated with aberrant expression of the genes encoding the secreted proteins Futrin 1, 2, 3 and/or 4 (=R-Spondin 2, 3, 1 and 4, respectively), e.g. in connection with tumors or diseases of the muscle, kidneys or bones. The present invention also relates to a pharmaceutical composition containing a compound which is capable of modifying (a) the expression of the gene encoding Futrin 1, 2, 3 and/or 4 or (b) the activity of the Futrin 1, 2, 3 and/or 4 protein. | 05-15-2014 |
20140186917 | Compositions for Diagnosis and Therapy of Diseases Associated with Aberrant Expression of Futrins (R-Spondins) and/or Wnt - The present invention relates to a composition useful for the diagnosis of diseases associated with aberrant expression of the genes encoding the secreted proteins Futrin 1, 2, 3 and/or 4(=R-Spondin 2, 3, 1 and 4, respectively), e.g. in connection with tumors or diseases of the muscle, kidneys or bones. The present invention also relates to a pharmaceutical composition containing a compound which is capable of modifying (a) the expression of the gene encoding Futrin 1, 2, 3 and/or 4 or (b) the activity of the Futrin 1, 2, 3 and/or 4 protein. | 07-03-2014 |
20140357510 | Compositions for Diagnosis and Therapy of Diseases Associated with Aberrant Expression of Futrins (R-Spondins) and/or Wnt - The present invention relates to a composition useful for the diagnosis of diseases associated with aberrant expression of the genes encoding the secreted proteins Futrin 1, 2, 3 and/or 4 (=R-Spondin 2, 3, 1 and 4, respectively), e.g. in connection with tumors or diseases of the muscle, kidneys or bones. The present invention also relates to a pharmaceutical composition containing a compound which is capable of modifying (a) the expression of the gene encoding Futrin 1, 2, 3 and/or 4 or (b) the activity of the Futrin 1, 2, 3 and/or 4 protein. | 12-04-2014 |
Patent application number | Description | Published |
20110011300 | MOTOR ACTIVATION CIRCUIT FOR A RAIL VEHICLE AND METHOD FOR THE OPERATION THEREOF - A motor drive circuit for a rail vehicle has a step-up converter, which is disposed at the input of the motor drive circuit, and which converts a mains DC voltage, at the input of the motor drive circuit into an intermediate circuit DC voltage. A pulse rectifier, which is downstream from the step-up converter, can be connected at the output to a drive motor of the rail vehicle and it is capable of converting the intermediate circuit DC voltage of the step-up converter into a motor drive voltage for driving the drive motor. A control unit activates the step-up converter in operation such that the converter generates the predetermined rated intermediate circuit DC voltage for a mains DC voltage below a predetermined rated intermediate circuit DC voltage as the intermediate circuit DC voltage. The control unit is designed such that it activates the step-up converter for a mains DC voltage above the rated intermediate circuit DC voltage such that the converter generates an intermediate circuit DC voltage identical to the mains DC voltage or an intermediate circuit DC voltage, which is greater at most by a predetermined offset value, and feeds the intermediate circuit DC voltage into the pulse rectifier. | 01-20-2011 |
20150028831 | VOLTAGE SETTING DEVICE - A voltage setting device has at least one multi-step voltage output, at least one power converter unit, which has at least one first power element that forms at least a part of a power converter branch, and a control unit that controls the first power element according to a first voltage step structure to provide a branch voltage. The power converter unit includes at least one second power element that, together with the first power element, forms the power converter branch and includes a group of modules, each with at least one energy storage device, a switch group and a module output. In a given control mode the control unit controls the group of modules to provide the branch voltage in cooperation with the first power element according to a second voltage step structure which is more detailed than the first voltage step structure. | 01-29-2015 |
Patent application number | Description | Published |
20080318957 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF - Disclosed are compounds having polybasic functionalities. The compounds inhibit bacterial efflux pump inhibitors and are used in combination with an anti-bacterial agent to treat or prevent bacterial infections. These combinations can be effective against bacterial infections that have developed resistance to anti-bacterial agents through an efflux pump mechanism. | 12-25-2008 |
20090239896 | AZAINDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS - Indole and indole-related compounds, compositions and methods are disclosed. The compounds of the invention are useful as phospholipase inhibitors. The compounds and compositions of the invention are useful for treatment of phospholipase-related conditions, such as insulin-related, weight-related and/or cholesterol-related conditions in an animal subject. The compounds include azaindoles of the formula below [insert FIG. | 09-24-2009 |
20090306171 | INDOLE COMPOUNDS HAVING C4-AMIDE SUBSTITUENTS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS - Indole and indole-related compounds according to the formula (I) or (II) optionally having additional heteroatoms, compositions and methods are disclosed. The compounds of the invention are useful as phospholipase inhibitors. The compounds and compositions of the invention are useful for treatment of phospholipase-related conditions, such as insulin-related, weight-related and/or cholesterol-related conditions in an animal subject. Formula (I), formula (II). R | 12-10-2009 |
20090318492 | INDOLE COMPOUNDS HAVING C4-ACIDIC SUBSTITUENTS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS - Indole and indole-related compounds, compositions and methods are disclosed. The compounds of the invention are useful as phospholipase inhibitors. The compounds and compositions of the invention are useful for treatment of phospholipase-related conditions, such as insulin-related, weight-related and/or cholesterol-related conditions in an animal subject. | 12-24-2009 |
20100152098 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF - Disclosed are compounds having polybasic functionalities. The compounds inhibit bacterial efflux pump inhibitors and are used in combination with an anti-bacterial agent to treat or prevent bacterial infections. These combinations can be effective against bacterial infections that have developed resistance to anti-bacterial agents through an efflux pump mechanism. | 06-17-2010 |
20120165276 | QUATERNARY ALKYL AMMONIUM BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF - Disclosed are compounds having at least one quaternary alkyl ammonium functionality. The compounds inhibit bacterial efflux pump inhibitors and are used in combination with an anti-bacterial agent to treat or prevent bacterial infections. These combinations can be effective against bacterial infections that have developed resistance to anti-bacterial agents through an efflux pump mechanism. | 06-28-2012 |
20130316943 | BORON CONTAINING POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF - Disclosed herein are polybasic bacterial efflux pump inhibitors containing boronic acid functionality and their methods of synthesis, methods of use, and pharmaceutical compositions. Some embodiments include methods of treating or preventing a bacterial infection by co-administering to a subject infected with bacteria or at risk of infection with bacteria the efflux pump inhibitor with another anti-bacterial agent. | 11-28-2013 |
20130316978 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF - Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents. | 11-28-2013 |
20140194381 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF - Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents. | 07-10-2014 |
20140194382 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF - Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents. | 07-10-2014 |
20140194384 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF - Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents. | 07-10-2014 |
20140194385 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF - Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents. Other embodiments relate to pharmaceutical compositions containing boronic acid derivatives and additional excipient such as meglumine. | 07-10-2014 |
20140275007 | OXAMAZIN ANTIBIOTICS - Disclosed herein are oxamazin monobactam compounds and their use as antibiotics resistant to degradation by β-lactamases. Also disclosed are pharmaceutical compositions containing the compounds and methods of synthesis. | 09-18-2014 |